FIELD: pharmaceuticals; medicine.
SUBSTANCE: object 1 is a solid dispersion of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol in a polymer matrix consisting of a copolymer of polyvinylpyrrolidone and polyvinyl acetate to sensitize cancer cells to ionizing radiation. Object 2 is a pharmaceutical composition for sensitizing cancer cells to ionizing radiation, which is a tablet containing a solid dispersion. Objects 3 and 4 are the methods of preparing a solid dispersion. Object 5 is a method of preparing a pharmaceutical composition.
EFFECT: improved bioavailability of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol.
13 cl, 3 dwg, 5 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARYLQUINAZOLINES | 2014 |
|
RU2701193C2 |
| PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
| HARD, SUITABLE FOR ORAL INTAKE PHARMACEUTICAL FORMS OF APPLICATION, CONTAINING RIVAROXABAN WITH MODIFIED RELEASE | 2005 |
|
RU2420290C2 |
| PERORAL SOLID DOSAGE FORM WITH MYCOPHENOLIC ACID OR ITS SALT FOR USE AS AN IMMUNODEPRESSANT FOR TREATMENT OR PREVENTION OF ORGAN OR TISSUE TRANSPLANT REJECTION AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2670447C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
| DERIVATIVES OF QUINAZOLINE | 2003 |
|
RU2296757C2 |
| EXTRUDATE WITH SODIUM MYCOPHENOLATE TO PRODUCE PERORAL SOLID DOSAGE FORM | 2018 |
|
RU2723255C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING SIGMA RECEPTOR LIGANDS | 2010 |
|
RU2549882C2 |
| SOLID DISPERSIONS, CONTAINING KINASE INHIBITORS | 2011 |
|
RU2566716C2 |
| COMPOSITION AND DOSAGE FORM CONTAINING SOLID OR SEMISOLID MATRIX | 2006 |
|
RU2423997C9 |
